Madison Investments, an investment advisor, released its “Madison Small Cap Fund” fourth-quarter 2024 investor letter. A copy ...

Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company ...

LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Clinical research company Medpace Holdings (NASDAQ:MEDP) in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On ...

LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Q4 2024 Earnings Call Transcript February 11, 2025 Operator: And good day, ladies and gentlemen, and welcome to the Medpace ...

Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a ...

Equities research analysts at William Blair decreased their Q3 2025 earnings estimates for Medpace in a research report ...

Analysts at William Blair raised their Q1 2025 EPS estimates for shares of Medpace in a research note issued to investors on ...

Medpace forecasts 2025 revenue between $2.11 billion and $2.21 billion, representing flat to 4.8% growth. EBITDA is expected in the range of $462 million to $492 million, reflecting a potential ...

Medpace has had an excellent financial performance. Its revenues increased by 495.26% between 2016Q2 and 2024Q3. Meanwhile, its current ROE is 54.08%. The company focused on small and mid-size ...

Narrow-moat Medpace reported mixed 2024 results. Revenue increased to $2.1 billion, up 11.8% from $1.9 billion in 2023, but the company continues to face challenges from elevated cancellation ...